Spironolactone: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
===''[[Spironolactone|Spironolactone]]''=== | ===''[[Spironolactone|Spironolactone]]''=== | ||
* [[ | * [[Aldactone]] | ||
===''[[Spironolactone/Hydrochlorothiazide|Spironolactone/Hydrochlorothiazide]]''=== | ===''[[Spironolactone/Hydrochlorothiazide|Spironolactone/Hydrochlorothiazide]]''=== | ||
Revision as of 17:33, 11 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Spironolactone
Spironolactone/Hydrochlorothiazide
Overview
Spironolactone is a competitive, β1-selective (cardioselective) blocker used in treatment of angina pectoris, hypertension, arrhythmia, and migraine. Common adverse reactions include bradyarrhythmia, heart block, heart failure, hypotension, pruritus, rash, constipation, diarrhea, indigestion, nausea, dizziness, fatigue, headache, depression, dyspnea, and wheezing.
The active substance metoprolol is employed either as metoprolol succinate or as metoprolol tartrate. The tartrate is an immediate-release and the succinate is an extended-release formulation.
Category
Aldosterone Antagonist